vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $339.0M, roughly 1.0× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -6.6%, a 19.8% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $27.8M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
HAE vs WEST — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $339.5M |
| Net Profit | $44.7M | $-22.6M |
| Gross Margin | 59.7% | 11.5% |
| Operating Margin | 19.9% | -2.6% |
| Net Margin | 13.2% | -6.6% |
| Revenue YoY | -2.7% | 48.3% |
| Net Profit YoY | 19.3% | 8.3% |
| EPS (diluted) | $0.95 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $339.5M | ||
| Q3 25 | $327.3M | $354.8M | ||
| Q2 25 | $321.4M | $280.9M | ||
| Q1 25 | $330.6M | $213.8M | ||
| Q4 24 | $348.5M | $229.0M | ||
| Q3 24 | $345.5M | $220.9M | ||
| Q2 24 | $336.2M | $208.4M | ||
| Q1 24 | — | $192.5M |
| Q4 25 | $44.7M | $-22.6M | ||
| Q3 25 | $38.7M | $-19.1M | ||
| Q2 25 | $34.0M | $-21.6M | ||
| Q1 25 | $58.0M | $-27.2M | ||
| Q4 24 | $37.5M | $-24.6M | ||
| Q3 24 | $33.8M | $-14.3M | ||
| Q2 24 | $38.4M | $-17.8M | ||
| Q1 24 | — | $-23.7M |
| Q4 25 | 59.7% | 11.5% | ||
| Q3 25 | 59.5% | 11.7% | ||
| Q2 25 | 59.8% | 14.7% | ||
| Q1 25 | 58.4% | 13.6% | ||
| Q4 24 | 55.5% | 16.6% | ||
| Q3 24 | 54.2% | 16.8% | ||
| Q2 24 | 52.0% | 19.9% | ||
| Q1 24 | — | 19.4% |
| Q4 25 | 19.9% | -2.6% | ||
| Q3 25 | 17.9% | -2.4% | ||
| Q2 25 | 16.8% | -5.3% | ||
| Q1 25 | 21.6% | -6.1% | ||
| Q4 24 | 16.9% | -4.3% | ||
| Q3 24 | 15.0% | -5.8% | ||
| Q2 24 | 11.8% | -7.9% | ||
| Q1 24 | — | -5.3% |
| Q4 25 | 13.2% | -6.6% | ||
| Q3 25 | 11.8% | -5.4% | ||
| Q2 25 | 10.6% | -7.7% | ||
| Q1 25 | 17.5% | -12.7% | ||
| Q4 24 | 10.8% | -10.7% | ||
| Q3 24 | 9.8% | -6.5% | ||
| Q2 24 | 11.4% | -8.5% | ||
| Q1 24 | — | -12.3% |
| Q4 25 | $0.95 | $-0.22 | ||
| Q3 25 | $0.81 | $-0.20 | ||
| Q2 25 | $0.70 | $-0.23 | ||
| Q1 25 | $1.17 | $-0.29 | ||
| Q4 24 | $0.74 | $-0.26 | ||
| Q3 24 | $0.66 | $-0.16 | ||
| Q2 24 | $0.74 | $-0.20 | ||
| Q1 24 | — | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $49.9M |
| Total DebtLower is stronger | $1.2B | $444.1M |
| Stockholders' EquityBook value | $911.5M | $-1.9M |
| Total Assets | $2.5B | $1.2B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $49.9M | ||
| Q3 25 | $296.4M | $34.0M | ||
| Q2 25 | $292.9M | $44.0M | ||
| Q1 25 | $306.8M | $33.1M | ||
| Q4 24 | $320.8M | $26.2M | ||
| Q3 24 | $299.3M | $22.4M | ||
| Q2 24 | $344.4M | $24.3M | ||
| Q1 24 | — | $12.6M |
| Q4 25 | $1.2B | $444.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $-1.9M | ||
| Q3 25 | $849.2M | $11.4M | ||
| Q2 25 | $882.3M | $18.2M | ||
| Q1 25 | $820.8M | $71.4M | ||
| Q4 24 | $906.9M | $97.5M | ||
| Q3 24 | $878.9M | $110.3M | ||
| Q2 24 | $905.4M | $81.5M | ||
| Q1 24 | — | $91.7M |
| Q4 25 | $2.5B | $1.2B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.5B | $1.1B | ||
| Q4 24 | $2.5B | $1.1B | ||
| Q3 24 | $2.5B | $1.1B | ||
| Q2 24 | $2.5B | $1.1B | ||
| Q1 24 | — | $983.3M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $36.7M |
| Free Cash FlowOCF − Capex | $87.2M | $27.8M |
| FCF MarginFCF / Revenue | 25.7% | 8.2% |
| Capex IntensityCapex / Revenue | 1.9% | 2.6% |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $36.7M | ||
| Q3 25 | $111.3M | $-26.6M | ||
| Q2 25 | $17.4M | $-7.0M | ||
| Q1 25 | $116.6M | $-22.1M | ||
| Q4 24 | $43.8M | $2.8M | ||
| Q3 24 | $48.8M | $-332.0K | ||
| Q2 24 | $-27.4M | $-23.7M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | $87.2M | $27.8M | ||
| Q3 25 | $106.3M | $-44.7M | ||
| Q2 25 | $13.6M | $-27.5M | ||
| Q1 25 | $100.9M | $-63.4M | ||
| Q4 24 | $35.2M | $-15.4M | ||
| Q3 24 | $39.4M | $-36.7M | ||
| Q2 24 | $-33.1M | $-59.9M | ||
| Q1 24 | — | $-60.9M |
| Q4 25 | 25.7% | 8.2% | ||
| Q3 25 | 32.5% | -12.6% | ||
| Q2 25 | 4.2% | -9.8% | ||
| Q1 25 | 30.5% | -29.7% | ||
| Q4 24 | 10.1% | -6.7% | ||
| Q3 24 | 11.4% | -16.6% | ||
| Q2 24 | -9.8% | -28.7% | ||
| Q1 24 | — | -31.7% |
| Q4 25 | 1.9% | 2.6% | ||
| Q3 25 | 1.5% | 5.1% | ||
| Q2 25 | 1.2% | 7.3% | ||
| Q1 25 | 4.7% | 19.3% | ||
| Q4 24 | 2.5% | 7.9% | ||
| Q3 24 | 2.7% | 16.5% | ||
| Q2 24 | 1.7% | 17.4% | ||
| Q1 24 | — | 35.8% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
